{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:02:39Z","timestamp":1777982559465,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06927-z","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:11:12Z","timestamp":1774253472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of 30-day readmissions post-CAR-T in patients with relapsed\/refractory multiple myeloma using the United States nationwide readmission database"],"prefix":"10.1007","volume":"105","author":[{"given":"Raj","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Vojjala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiewei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmi","family":"Bhanushali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjana","family":"Mullangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"8","key":"6927_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"10297","key":"6927_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"6","key":"6927_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG et al (2023) Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 41(6):1265\u20131274. https:\/\/doi.org\/10.1200\/JCO.22.00842","journal-title":"J Clin Oncol"},{"issue":"9","key":"6927_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","volume":"30","author":"W Wesson","year":"2024","unstructured":"Wesson W, Dima D, Suleman N et al (2024) Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma. Transpl Cell Ther 30(9):876\u2013884. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.012","journal-title":"Transpl Cell Ther"},{"issue":"27","key":"6927_CR5","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L et al (2020) Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol 38(27):3119\u20133128. https:\/\/doi.org\/10.1200\/JCO.19.02104","journal-title":"J Clin Oncol"},{"issue":"6","key":"6927_CR6","first-page":"584","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Bishop M, Ayuk F et al (2024) Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transpl Cell Ther 30(6):584. .e1-584.e13","journal-title":"Transpl Cell Ther"},{"issue":"15","key":"6927_CR7","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M et al (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4(15):3776\u20133787. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509","journal-title":"Blood Adv"},{"issue":"2","key":"6927_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P et al (2020) Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105(2):297\u2013316. https:\/\/doi.org\/10.3324\/haematol.2019.229781","journal-title":"Haematologica"},{"issue":"1","key":"6927_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/clinchem\/hvad179","volume":"70","author":"T Mamo","year":"2024","unstructured":"Mamo T, Dreyzin A, Stroncek D, McKenna DH (2024) Emerging Biomarkers for Monitoring Chimeric Antigen Receptor T-Cell Therapy. Clin Chem 70(1):116\u2013127. https:\/\/doi.org\/10.1093\/clinchem\/hvad179","journal-title":"Clin Chem"},{"issue":"6","key":"6927_CR10","first-page":"349","volume":"31","author":"FL Locke","year":"2025","unstructured":"Locke FL, Mahmoudjafari Z, Kebriaei P et al (2025) Awakening from REMS: ASTCT 80\/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transpl Cell Ther 31(6):349. .e1-349.e12","journal-title":"Transpl Cell Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06927-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06927-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:16Z","timestamp":1776405556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06927-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6927"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06927-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8571194\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Grant support"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}